Please wait

Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

NewAmsterdam Pharma Company N.V.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

                 
    

Security

Type

 

Security

Class

Title

 

Fee

Calculation 

Rule

 

Amount

Registered 

 

Proposed

Maximum 

Offering

Price Per

Unit

 

Maximum

Aggregate

Offering

Price

 

Fee

Rate

 

Amount of

Registration

Fee

                 

Fees to be 

Paid 

  Equity   Ordinary Shares, nominal value EUR 0.12   Rule 457(o)       (1)   (1)    
  Other   Warrants to purchase ordinary shares, nominal value EUR 0.12   Rule 457(o)       (1)   (1)        
 

Unallocated

(Universal) Shelf

    Rule 457(o)   (1)   (1)   $78,975,000    0.00015310    $12,091.08 
                 

Fees  Previously 

Paid 

  N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A
           
    Total Offering Amounts        $78,975,000       

$12,091.08 

           
    Total Fees Previously Paid                $—
           
    Total Fee Offsets                $—
           
    Net Fee Due               

$12,091.08 

 

(1)

The Registrant previously registered the offer and sale of its securities, including ordinary shares, nominal value EUR 0.12 (the “Ordinary Shares”) and warrants to purchase Ordinary Shares, having a proposed maximum aggregate offering price of $400,000,000 pursuant to a Registration Statement on Form S-3 (File No. 333-280687), which was filed by the Registrant on July 3, 2024 and declared effective by the Securities and Exchange Commission on July 12, 2024 (the “Prior Registration Statement”). As of the date hereof, a balance of $400,000,000 of such securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”), and General Instruction IV(A) of Form S-3, the Registrant is hereby registering the offer and sale of an additional $78,975,000 of its Ordinary Shares and warrants to purchase Ordinary Shares representing no more than 20% of the maximum aggregate offering price of securities remaining available for issuance under the Prior Registration Statement. Pursuant to Rule 416 under the Securities Act, this Registration Statement shall also cover any additional securities of the Registrant that become issuable by reason of any splits, dividends or similar transactions or anti-dilution adjustments.